^
    Back
    Association details:
    Biomarker:ARID1A mutation
    Cancer:Bladder Cancer
    Drug:GSK2816126 (EZH2 inhibitor)
    Direction:Sensitive
    Evidence:
    Evidence Level:
    Sensitive: D – Preclinical
    Source:
    AUA 2020
    Title:

    PD42-07: Investigating the synthetic lethality of Enhancer of zeste homolog 2 (EZH2) inhibition in AT-rich interactive domain-containing protein 1A (ARID1A) mutant bladder cancer

    Published date:
    05/15/2020
    Excerpt:
    In silico analysis (TCGA) compared disease-free survival (DFS) between ARID1A mutant (ARID1Amut) and wildtype (wt) tumors. Cell proliferation assays were performed with/without EZH2 inhibitor GSK-126. ARID1A mutation is a biomarker for EZH2 inhibitor sensitivity in BCa cells...